{"entity":{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","aka":[],"tldr":"German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma.","summary":"Ralf Gutzmer is a German dermato-oncologist who led skin cancer research at Hannover Medical School before moving to the Mühlenkreiskliniken in Minden. He was first author of the 2020 Lancet report of IMspire150, the phase 3 trial in which atezolizumab plus vemurafenib and cobimetinib lengthened progression-free survival compared with the two targeted drugs alone in untreated BRAF V600-mutant advanced melanoma, the first approval of a triplet combining immunotherapy and BRAF-MEK inhibition.","asOf":"2026-09-18","links":[],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["braf-v600-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["imspire150"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Dermato-oncologist and trial lead","specialisms":["Melanoma","Targeted plus immunotherapy combinations","Dermato-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutzmer%5BAuthor%5D"}],"papers":[]},"route":"/people/ralf-gutzmer/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"trial":[{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/"}]}}